Precision Oncology Market Growth & Trends
The global precision oncology market size is expected to reach USD 201.96 billion by 2030, registering a CAGR of 8.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.
Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.
In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna’s TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.
Precision Oncology Market Report Highlights
- Based on product type, the therapeutics segment led the market with the largest revenue share of 71.3% in 2024, due to the increasing development and approval of targeted treatments tailored to specific genetic mutations.
- Based on cancer type, the breast cancer segment led the market with the largest revenue share of 41.7% in 2024, attributed to increasing awareness for breast cancer screening, diagnosis, and surgical and radiation techniques.
- Based on end-use, the hospitals and diagnostic segment led the market with the largest revenue share of 46.8% in 2024. In hospital and diagnostic, precision oncology products are garnering an increasing amount of interest worldwide as it emphases molecular profiling of tumors to identify alterations in the gene.
- North America precision oncology market dominated with the largest revenue share of 44.0% in 2024. The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product Type
- 1.2.2. Cancer Type
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product type outlook
- 2.2.2. Cancer type outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Precision Oncology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising Prevalence of Cancer
- 3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
- 3.2.1.3. Supportive Government and Private Sector Initiatives
- 3.2.2. Market restraint analysis
- 3.2.2.1. High Costs of Precision Oncology Therapies
- 3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
- 3.3. Precision Oncology Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis
- 4.1. Product Type Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Precision Oncology Market by Product Type Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Diagnostics
- 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.2. Therapeutics
- 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis
- 5.1. Cancer Type Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Precision Oncology Market by Cancer Type Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Breast Cancer
- 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2. Colorectal Cancer
- 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. Cervical Cancer
- 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.4. Prostate Cancer
- 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.5. Lung Cancer
- 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.6. Others
- 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis
- 6.1. End Use Market Share, 2024 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Precision Oncology Market by End Use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Hospitals and Diagnostic
- 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.2. Pharmaceutical and Biotechnology
- 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.3. Healthcare Data Companies
- 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Target disease prevalence
- 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Target disease prevalence
- 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.3. Mexico
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. Target disease prevalence
- 7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
- 7.6. Europe
- 7.6.1. UK
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Target disease prevalence
- 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.2. Germany
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Target disease prevalence
- 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. Target disease prevalence
- 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Target disease prevalence
- 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. Target disease prevalence
- 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Target disease prevalence
- 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Regulatory framework/ reimbursement structure
- 7.6.7.3. Competitive scenario
- 7.6.7.4. Target disease prevalence
- 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Regulatory framework/ reimbursement structure
- 7.6.8.3. Competitive scenario
- 7.6.8.4. Target disease prevalence
- 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Target disease prevalence
- 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Target disease prevalence
- 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. Target disease prevalence
- 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Target disease prevalence
- 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Regulatory framework/ reimbursement structure
- 7.7.5.3. Competitive scenario
- 7.7.5.4. Target disease prevalence
- 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Regulatory framework/ reimbursement structure
- 7.7.6.3. Competitive scenario
- 7.7.6.4. Target disease prevalence
- 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. Target disease prevalence
- 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.8.2. Argentina
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Target disease prevalence
- 7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Regulatory framework/ reimbursement structure
- 7.9.1.3. Competitive scenario
- 7.9.1.4. Target disease prevalence
- 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Regulatory framework/ reimbursement structure
- 7.9.2.3. Competitive scenario
- 7.9.2.4. Target disease prevalence
- 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Regulatory framework/ reimbursement structure
- 7.9.3.3. Competitive scenario
- 7.9.3.4. Target disease prevalence
- 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Regulatory framework/ reimbursement structure
- 7.9.4.3. Competitive scenario
- 7.9.4.4. Target disease prevalence
- 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company market share analysis, 2024
- 8.3.2. Thermo Fisher Scientific Inc.
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Product benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Invitae Corporation
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Qiagen N.V.
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Illumina, Inc.
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Laboratory Corporation of America Holding
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Exact Sciences Corporation
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Rain Oncology Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Strata Oncology Inc.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Xilis, Inc.
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Variantyx, Inc.
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Bioserve
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Relay Therapeutics
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
- 8.3.14. Acrivon Therapeutics
- 8.3.14.1. Company overview
- 8.3.14.2. Financial performance
- 8.3.14.3. Product benchmarking
- 8.3.14.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook